CAJ | 학술논문

目的评估托吡酯与丙戊酸钠在治疗小儿癫痫的疗效及安全性的差异.方法54名癫痫患儿随机分为托吡酯治疗组(n=30)与丙戊酸钠治疗组(n=24).托吡酯治疗组接受托吡酯治疗,剂量从每晚1次1-3mg·kg-1·d-1(最大:25mg)增加到5-9mg·kg-1·d-1,分2次;丙戊酸钠治疗组接受丙戊酸钠20mg/kg(分2次),逐渐加量,严重病例在检测血药浓度情况下,可加量至最高40mg/kg.记录住院期间的可能副作用.结果两组总有效率分别为70%、66.7%%,差异不具有统计学意义(P=0.793);不良反应发生率分别为26.67%和16.67%,差异不具有统计学意义(P=0.583).结论治疗小儿癫痫,托吡酯与丙戊酸钠的有效性及安全性不存在明显差异.
목적평고탁필지여병무산납재치료소인전간적료효급안전성적차이.방법54명전간환인수궤분위탁필지치료조(n=30)여병무산납치료조(n=24).탁필지치료조접수탁필지치료,제량종매만1차1-3mg·kg-1·d-1(최대:25mg)증가도5-9mg·kg-1·d-1,분2차;병무산납치료조접수병무산납20mg/kg(분2차),축점가량,엄중병례재검측혈약농도정황하,가가량지최고40mg/kg.기록주원기간적가능부작용.결과량조총유효솔분별위70%、66.7%%,차이불구유통계학의의(P=0.793);불량반응발생솔분별위26.67%화16.67%,차이불구유통계학의의(P=0.583).결론치료소인전간,탁필지여병무산납적유효성급안전성불존재명현차이.
Objective To evaluate the efficacy and safety of topiramate versus sodium valproate in children with epilepsy. Methods 54 cases children with epilepsy randomly divided into topiramate group(n=30) and sodium valproate group(n=24). Topiramate group received topiramate from 1-3mg·kg-1·d-1(maximum: 25mg) given nightly, increased to 5-9mg·kg-1·d-1 given in 2 divided doses; Sodium valproate group was given sodium valproate 20mg/kg daily in 2 divided doses, increased gradually to 40mg/kg daily with serum valproic acid monitoring in severe cases. Suspected adverse drug reactions(ADRs) occurring during hospitalization were documented. Results The total effectiveness of topiramate group, sodium valproate group were 70%, 66.67%, no significant differences in two groups(P=0.793). There was no significant difference in ADRs between the two groups(26.67% Vs 16.67%, P=0.583). Conclusion There is no substantial differences in efficacy and safety appear to exist when topiramate is compared with sodium valproate in treating children with epilepsy.